Phase 2,3 trial data of India's first mRNA COVID vaccine submitted to DCGI: Report
Pune-based Gennova Biopharmaceuticals has also developed an Omicron-specific vaccine which will be tested on humans for efficacy and immunogenicity.
NEW DELHI : Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India's first mRNA COVID vaccine to the regulator Drugs Controller General of India (DCGI) on Friday, said sources.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more